简介:ThenickelcatalystSHN-01/Fforone-stagehydrotreatingofpyrolysisgasolinedevelopedbySINOPECShanghaiPetrochemicalResearchInstitutehassuccessfullycompletedcommercialtests,symbolizingthebeginningofcommercialapplicationphaseofthisnickel-basedcatalystforone-stagehydrotreatingofpyrolysisgasolinewithSINOPEC'sindependentintellectualpropertyrights.
简介:Objective:ToinvestigatetherelationshipbetweenNAD(P)H:quinoneoxidoreductase1(NQO1)C609TpolymorphismandcoloncancerriskinfarmersfromwesternregionofInnerMongolia.Methods:Polymerasechainreaction-restrictionfragmentlengthpolymorphism(PCR-RFLP)wasperformedtoanalyzeNQO1C609Tpolymorphismfrom160healthycontrolsand76coloncancerpatients.Results:Amongthecoloncancerpatients,theincidenceofNQO1Tallele(53.29%)wassignificantlyhigherthanitincontrolgroup(33.75%,P<0.001).TheindividualswithNQO1Tallelehadhigherrisk[2.239(95%CI:1.510-3.321)times]todevelopcoloncancerthanindividualswithNQO1Callele.TheincidenceofNQO1(T/T)(34.21%)incoloncancerpatientswashigherthanthatincontrolgroup(15.62%,P<0.001).Oddsratios(OR)analysissuggestedthatNQO1(T/T)andNQO1(T/C)genotypecarriershad3.813(95%CI:1.836-7.920)timesand2.080(1.026-4.219)timesriskcomparedwithwild-typeNQO1(C/C)genecarriersindevelopingcoloncancer.IndividualswithNQO1(T/T)genotypehad2.541(95%CI:0.990-6.552)times,3.713(95%CI:1.542-8.935)times,and3.471(95%CI:1.356-8.886)timesriskthanindividualswithNQO1(T/C)orNQO1(C/C)genotypeinwelldifferentiated,moderately-differentiated,andpoorly-differentiatedcoloncancerpatients,respectively.Conclusions:NQO1geneC609TcouldbeoneofriskfactorsofcoloncancerinfarmersfromwesternregionofInnerMongolia.
简介:EDITOR'SNOTE:TheInformationOfficeoftheStateCouncil,orChina'scabinet,publishedtheNationalHumanRightsActionPlanofChina(2012-2015)onMonday.Followingisthefulltext.TheformulationofthenationalhumanRightsactionPlanisanimportantmeasuretakenbytheChinesegovernmenttoensuretheimplementationoftheconstitutionalprincipleofrespectingand
简介:化合物YSY-01A是一种新合成的蛋白酶体抑制剂,前期研究已经证实其具有良好的抑制肿瘤增殖作用。但是其作用机制尤其是对细胞周期的阻滞作用仍不清楚。本实验旨在评价YSY-01A的抗肿瘤作用与细胞周期阻滞的关系,并探讨可能的分子机制。实验结果证实,YSY-01A能够显著抑制大肠腺癌细胞HT-29的增殖(P〈0.05),且具有浓度和时间依赖性。进一步实验表明,YSY-01A能够把HT-29细胞阻滞在G2/M转换点上,显著地上调cyclinB1,Wee1,p-cdc2(Tyr15)及p53,p21,p27蛋白的表达(P〈0.05)。当YSY-01A浓度高于0.5μM时,HT-29会显示出典型的细胞毒症状,差异具有显著性(P〈0.05);而本文用于机制研究的药物浓度均低于此值。总之,YSY-01A对HT-29细胞具有显著的增殖抑制作用,其分子机制与G2/M转换点阻滞有关。
简介:Ⅱ,MaiorproblemsexistinginChinarare-earthindustry1.SlowdevelopmentofrareearthapplicationtechnologyandstagnantupgradeoftheindustrystructureTherearesomeproblemsexistinginChinarareearthindustrycurrently,includingweakdevelopmentofnewrareearthapplicationtechnologies,slowindustrializationofresearchachievements.
简介:目的了解深圳市2002-2009年CRF01-AE亚型Env基因V3环变异特征。方法采用Nested-PCR扩增Env区,对扩增产物进行测序,利用MEGA软件进行基因序列整理和分析。结果从2002-2009年,深圳市CRF01-AE亚型Env基因离散率从9.09%增长至13.13%,呈逐年递增趋势;共发现10种V3环顶端四肽类型,其中主要类型为GPGQ(77.38%)、GPGR(16.32%),所有类型顶端四肽比例在各年份存在上下波动趋势;每个时间段都有至少91.00%毒株使用CCR5作为辅助受体,1.00%~9.00%毒株不能做出预测,没有可被预测为使用CXCR4为辅助受体的毒株。结论从2002-2009年深圳市CRF01-AE亚型病毒变异随流行时间不断加大;V3环顶端四肽类型中GPGR比例变化最大;深圳地区大部分CRF01-AE毒株为巨噬细胞嗜性。